United States - English - NLM (National Library of Medicine)

clinimmune labs, university of colorado blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 30 ml - hpc (hematopoietic progenitor cells), cord blood is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. hpc, cord blood is contraindicated in patients with known hypersensitivity to dimethyl sulfoxide (dmso), dextran 40 or plasma proteins. [see description (11) and dosage and administration (2.2)] pregnancy category c. animal reproduction studies have not been conducted with hpc, cord

United States - English - NLM (National Library of Medicine)

university of texas md anderson cancer center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - hematopoietic progenitor cell (hpc), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the benefit-risk assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with hpc, cord blood use in pregnant women to inform a product-associated risk.  animal reproduction studies have not been conducted with hpc, cord blood. in the u.s. general population, the estimated background risk of major birth defects and misc

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - carboprost tromethamine (unii: u4526f86fj) (carboprost - unii:7b5032xt6o) - carboprost 250 ug in 1 ml - hemabate sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: - failure of expulsion of the fetus during the course of treatment by another method; - premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; - requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; - inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. hemabate is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - hematology - liquichek hematology control (a) is an assayed whole blood control designed to monitor values on multi-parameter hematology cell counters. liquichek hematology control(a) is available as trilevel (p/n:865),low level (p/n:866), normal level (p/n:867), high level (p/n:868) and trilevel minipak(p/n:865x).

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - acalabrutinib (unii: i42748elqw) (acalabrutinib - unii:i42748elqw) - acalabrutinib 100 mg - calquence is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy. this indication is approved under accelerated approval based on overall response rate [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. calquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll). none. risk summary based on findings in animals, calquence may cause fetal harm and dystocia when administered to a pregnant woman. there are no available data in pregnant women to inform the drug-associated risk. in animal reproduction studies, administration of acalabrutinib to animals during organogenesis resulted in dystocia in rats and reduced fetal growth in rabbits at maternal exposures (auc) 2 times exposures in patients at the recommended dose of 100 mg approximately every 12 hours (s

United States - English - NLM (National Library of Medicine)

new york blood center - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 500000000 in 25 ml - hemacord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none pregnancy category c. animal reproduction studies have not been conducted with hemacord. it is also not known whether hemacord can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. there are no adequate and well-controlled st

United States - English - NLM (National Library of Medicine)

duke university school of medicine, carolinas cord blood bank - human cord blood hematopoietic progenitor cell (unii: xu53vk93mc) (human cord blood hematopoietic progenitor cell - unii:xu53vk93mc) - human cord blood hematopoietic progenitor cell 900000000 in 25 ml - ducord, hpc (hematopoietic progenitor cell), cord blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor stem cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. the risk benefit assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. none. risk summary there are no data with ducord use in pregnant women to inform a product-associated risk. animal reproduction studies have not been conducted with ducord. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - hematology - liquichek hematology control (s) is a control designed to monitor values obtained on siemens hematology analyzers.

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - hematology - liquichek hematology control (x) is a tri-level control designed to monitor values obtained on sysmex hematology analyzers.

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - hematology - bio-rad liquichek hematology-16 control low, normal and high is a hematology reference control used in monitoring determinations of blood cell values on cell counters. the parameters include gran (granulocytes), hct (hematocrit), hgb (hemoglobin), lymph (lymphocytes), mch (mean corpuscular hemoglobin), mchc (mean cospuscular hemoglobin concentration), mcv (mean cospuscular volume), mid (mid-sized cells), mono (monocytes), mpv (mean platelet volume), plt (platelets, rbc (red blood cells), rdw (red blood cell distribution width), wbc (white blood cells).